How innovation can reduce disparities in cancer care

Cancer doesn’t care where you live, what you earn, what language you speak, or whether your car decides to
“make a fun noise” on the way to your appointment. Unfortunately, the health system often cares a lot.
That mismatch is what we mean by disparities in cancer care: predictable differences in
prevention, screening, diagnosis, treatment, survivorship, and outcomes that track with race and ethnicity,
income, insurance coverage, geography (rural vs. urban), disability, and more.

The good news: innovationdone thoughtfullycan shrink those gaps. The complicated news:
innovation can also widen them if it’s designed for people who already have time, money, broadband, paid
leave, and a flexible ride. So the real question isn’t “Can technology fix disparities?” It’s
“Can we build equity-first innovation that makes the easier path the same path for everyone?”

Let’s dig into what’s working (and what needs guardrails), with concrete examples across screening,
navigation, telehealth, clinical trials, AI, and payment modelsbecause “download our app” is not a strategy
unless your app also comes with transportation, translation, and a human who calls back.

Why disparities happen (and why “more tech” isn’t automatically the answer)

Disparities are rarely caused by one single barrier. More often, it’s a stack of small frictions that add up:
a missed screening because the clinic is far; a late diagnosis because symptoms were dismissed; a treatment plan
that falls apart because chemotherapy means lost wages; a clinical trial that’s “open to everyone” but requires
three extra visits a week at a major academic center.

Innovation reduces disparities when it does one (or more) of these things:

• Moves care closer to people’s lives (home, community, or local clinics).
• Removes steps (fewer appointments, fewer forms, fewer “please call this other number”).
• Turns invisible barriers into solvable tasks (transportation, childcare, language, cost).
• Targets follow-up so abnormal tests don’t become “lost to the system.”
• Makes quality consistent across settings (rural hospitals, safety-net clinics, and big centers).

Now let’s look at the innovation areas that are most promising for reducing cancer care inequities.

1) Earlier detection with less friction

Many cancer disparities begin long before anyone says the words “treatment plan.” Screening and early detection
depend on access, trust, time, and convenienceso innovation that reduces hassle can be a major equity lever.

Mailed colorectal screening: letting the mailbox do some of the work

Colorectal cancer screening is a prime example where self-sampling and mail outreach can
increase participationespecially when paired with reminders, clear instructions, and navigation for follow-up.
Programs that mail fecal immunochemical tests (FIT) to patients (often coordinated by clinics and supported by
EHR prompts) have shown meaningful improvements in screening completion, including in safety-net settings.
When abnormal results happen, the system must “close the loop” with colonoscopy access and patient support,
or else the equity benefit evaporates.

The innovation here isn’t just the test. It’s the operational design: automated lists of overdue patients,
culturally appropriate materials, texting or phone reminders, prepaid return envelopes, and “warm handoffs” to
schedule follow-up colonoscopies. Think of it as replacing “good luck!” with an actual process.

Mobile mammography: the clinic that comes to you

Mobile mammography units can reach people who face transportation barriers, limited clinic
availability, or competing responsibilities. Evidence suggests mobile mammography is often used by women who
otherwise are less likely to be screened, which makes it a practical complement to facility-based screening.
It can also be paired with community outreach, navigation, and same-day scheduling to reduce missed opportunities.

Equity tip: mobile programs work best when they’re not “parachute medicine.” Partner with trusted community
organizations, align visit schedules with local events, and ensure results and follow-up are coordinatedbecause
a screening without follow-up is just an expensive postcard.

HPV testing innovations: self-collection options that reduce barriers

Cervical cancer is one of the clearest cases where disparities reflect missed prevention and missed screening.
Recent regulatory steps have expanded HPV testing with self-collection optionsinitially in
health care settings for people who can’t or don’t want a pelvic exam. Separately, the FDA has also approved
an at-home cervical cancer screening option for HPV testing (with a prescription pathway), which could further
reduce barriers if coverage and follow-up are equitable.

The equity opportunity is huge: self-collection can reduce discomfort, stigma, and logistics. The equity risk
is also real: if at-home tests are expensive, poorly covered, or harder to obtain for people without stable
internet access, we may accidentally create a “premium lane” for those who already have access.

Smarter eligibility for lung cancer screening: expanding who qualifies

Innovation isn’t only gadgetsit can also be better evidence-based guidelines. The USPSTF expanded lung cancer
screening recommendations (e.g., lowering the starting age and pack-year threshold), a change aimed in part at
improving access for groups who develop lung cancer at younger ages or with lower cumulative smoking exposure.
But implementation matters: screening can’t reduce disparities if eligible patients aren’t identified, referred,
and supported through annual follow-up.

Practical innovation: EHR-based identification of eligible patients, shared decision-making tools in plain
language, reminders, transportation support, and coordination with smoking cessation services. Because “annual”
means “annual,” not “we did it once and hoped for the best.”

2) Tech-enabled patient navigation: turning barriers into checklists

If cancer care were a video game, it would be one of those open-world games with no map, no tutorial, and a
side quest called “prior authorization.” Patient navigation exists because the system is complexand navigation
has strong evidence for improving outcomes and reducing disparities, especially around screening follow-up and
timely treatment.

The next wave is technology-enhanced navigation: using digital tools to make navigation more
scalable, more proactive, and less dependent on heroic improvisation. A 2024 report from the President’s Cancer
Panel specifically highlights how technology can strengthen evidence-based navigation by supporting coordination,
tracking, and communication.

What “innovation” looks like in navigation (hint: it’s not just an app)

• Closed-loop referral tracking: dashboards that flag patients who had abnormal screenings but
  haven’t completed diagnostic follow-up.
• Texting and reminders: multilingual messages that reduce no-shows and help patients prepare
  for procedures.
• Barrier screening embedded in workflows: quick checks for transportation, food insecurity,
  housing instability, and insurance issuespaired with actual resources, not just documentation.
• Scheduling automation with human backup: because automation without a human escape hatch is
  just a faster way to get stuck.
• Community-facing navigation: navigators and community health workers who coordinate across
  clinics, pharmacies, mobile units, and community sites.

Patient navigation research from national programs has emphasized supporting vulnerable patients through
abnormal screenings and cancer diagnosesexactly where disparities often widen. Technology can help, but only
when it’s paired with workforce investment and clear accountability for follow-up.

3) Telehealth and hybrid care that doesn’t leave people behind

Telehealth can reduce disparities when it cuts travel time, helps patients keep appointments, and brings
specialists into communities that don’t have them. It can also worsen disparities if it assumes every household
has broadband, a private room, a working smartphone, and comfort navigating portals in English.

Studies during and after the COVID-19 era have documented uneven telehealth use across demographic groups,
including lower utilization among some non-English speaking populations. That doesn’t mean telehealth is bad.
It means telehealth needs equity engineering.

Equity engineering for tele-oncology

• Offer multiple modalities: video, phone, asynchronous messaging, and in-personwithout penalizing patients for what they can access.
• Integrate interpreters smoothly: interpreter workflows should be one click, not a 12-step scavenger hunt.
• Provide digital support: device lending, “how-to” coaching, and portal training through navigators or community partners.
• Create community telehealth points: private rooms in clinics, libraries, or community centers for patients without home access.
• Use telehealth for what it does best: symptom checks, treatment education, survivorship care, second opinions, and care coordination.

The National Cancer Institute has emphasized the need for a strong research agenda on telehealth in cancer care
deliverybecause we don’t just need more telehealth. We need the right telehealth, for the right patients, in
the right workflows.

4) Remote symptom monitoring: catching problems earlier (and avoiding the ER)

Disparities aren’t only about access to the first appointment; they’re also about what happens between visits.
Patients with fewer resources may delay calling about symptoms, lack transportation for urgent evaluation, or
end up in emergency care when problems escalate.

Electronic patient-reported outcomes (ePROs) and remote symptom monitoring can help teams
catch issues earlierlike uncontrolled nausea, pain, dehydration, or infection riskby prompting patients to
report symptoms regularly and triggering clinical follow-up. Randomized trials have shown that electronic
symptom monitoring can improve patient-reported outcomes and reduce acute care use, and it has been discussed
as a strong fit for value-based oncology models.

Equity considerations: the reporting tool should work on basic phones, in multiple languages, with low literacy
options, and with human outreach when patients don’t respond. Otherwise, the “monitoring” becomes “monitoring
whoever has the easiest time logging in.”

5) Making clinical trials and advanced care reachable

Clinical trials are where tomorrow’s standard treatments are tested, but participation is often least accessible
to the people who shoulder the highest burdens of cancer mortality. That’s an equity problem and a science
problem: results are less generalizable when representation is poor.

Decentralized trials: meeting patients where they are

Decentralized and hybrid clinical trials can reduce participation barriers by allowing local
labs, local imaging, tele-visits, remote consent, and community sites. ASCO has emphasized the need to
streamline regulatory requirements and operational barriers to make decentralized trials more accessible while
maintaining data quality and safety.

Done right, decentralization can mean fewer days off work, less travel, and fewer “I would love to join, but…”
conversations. Done poorly, it can shift burdens onto patients (more self-management, more devices, more data
entry). Equity-first trial design builds in support: navigators, travel assistance when needed, and clear
communication.

Community-based research networks: bringing trials into communities

Programs like the NCI’s Community Oncology Research Program (NCORP) are designed to bring clinical trials and
cancer care delivery studies closer to where people liveincluding specific minority/underserved community sites.
This infrastructure matters because it reduces the “zip code tax” where living far from an academic center
quietly removes options.

Policy as innovation: Medicaid coverage for routine trial costs

Not all innovation is digital. The Clinical Treatment Act requires state Medicaid programs to
cover routine costs for qualifying clinical trials (effective January 1, 2022). That’s a direct hit on one of
the most stubborn barriers to equitable trial participation: affordability.

For equity impact, awareness and implementation matter. Patients and providers need to know the benefit exists,
and systems need workflows to avoid denials or confusion about what counts as “routine costs.”

6) AI, precision oncology, and the “fairness” requirement

AI is often marketed like a magic wand. In health equity, it’s more like a power tool: it can build a rampor
it can cut through the wrong wall if nobody checked the blueprint.

There are real opportunities:
AI-assisted imaging triage can help prioritize suspicious scans; clinical decision support can prompt guideline-based
care; risk models can identify patients overdue for screening; and data systems can spotlight where delays occur
(e.g., time from abnormal screen to biopsy).

But there are also real risks. AI can embed and amplify existing inequities when training data underrepresents
certain populations, when labels reflect biased care patterns, or when models aren’t evaluated across
demographic subgroups. Policy and oversight groups have argued for demographic performance analysis and bias
mitigation in medical AI review and deployment.

Equity guardrails for AI in cancer care

• Measure performance by subgroup: not just “overall accuracy,” but accuracy across age, race/ethnicity, sex, language, and site type.
• Monitor after deployment: model drift and workflow changes can quietly degrade equity over time.
• Keep humans in the loop: AI should support, not replace, clinical judgmentespecially when stakes are high.
• Design for safety-net settings: models trained only in well-resourced centers may fail where resources differ.
• Be transparent: explain what the tool does, what it misses, and what data it was trained on.

A simple rule: if an AI tool makes care faster for some patients and slower for others, it’s not “innovation.”
It’s just a new way to sort peopleusually by who already has fewer barriers.

7) Payment and delivery models that make equity scalable

The best equity innovation won’t last if it’s financed like a bake sale. Sustainability often depends on how care
is paid for. That’s why value-based oncology models matter: they can reward practices for coordination,
navigation, symptom monitoring, and addressing health-related social needsactivities that reduce disparities
but can be underfunded in fee-for-service environments.

For example, CMS’s Enhancing Oncology Model (EOM) is designed to incentivize coordinated, patient-centered care
for Medicare beneficiaries receiving chemotherapy for certain cancers. Models like this can create a financial
“home” for equity-supporting services like navigation, care planning, and outcomes monitoring.

Payment innovation won’t solve everything, but it can make it realistic for practices to invest in staff,
workflows, and technology that reduce delays and improve follow-upespecially in underserved communities.

What “equity-first innovation” looks like in practice

If you’re a health system leader, payer, startup, or community partner, here’s a practical checklist to keep
innovation from becoming “a shiny solution looking for people who already have solutions.”

Action steps that actually reduce disparities

1. Co-design with communities: build with patients, navigators, and community organizations from day one.
2. Start with friction points: follow-up after abnormal results, transportation barriers, language access, and time-to-treatment delays.
3. Make it work on the lowest-tech option: if it only works on the newest smartphone, it’s not an equity tool.
4. Measure equity outcomes: track screening completion, diagnostic follow-up, time to treatment, ED visits, and survival by subgroup.
5. Invest in navigation and closed-loop workflows: innovation should make it easier for humans to help humans.
6. Build coverage and affordability in: partner early with payers and policy stakeholders so access isn’t optional.
7. Plan the “last mile”: screening is step one; diagnostic and treatment follow-up is where disparities often widen.

Conclusion: innovation is a multiplierso choose what it multiplies

Innovation can reduce disparities in cancer care when it removes barriers, supports follow-up, and makes high-quality
care accessible beyond big centers. The most powerful innovations aren’t always the newest technology; they’re the ones
that fit real lives: mailed screening tests that don’t require a day off work, mobile clinics that come to
rural communities, navigation systems that track patients through the cracks, decentralized trials that reduce travel burdens,
and telehealth that’s designed for people with limited digital access.

If we treat equity as a feature, it will ship late (or never). If we treat equity as a requirement, innovation becomes
one of the strongest tools we have to make cancer outcomes less predictable by zip code, income, and identityand more
predictable by what matters: good prevention, good detection, and good care.

Experience snapshots: what innovation feels like on the ground (about )

The stories below are compositesbased on common experiences reported by patients, navigators, and cliniciansmeant to
show how equity-first innovation changes day-to-day reality. Because “reducing disparities” can sound abstract until you
picture the Tuesday it saves.

1) The mailed test that turns “someday” into “done”

Maria works two jobs and helps her dad with his appointments. She’s heard about colorectal cancer screening, but “schedule a colonoscopy”
lives in the same mental drawer as “learn Italian” and “sleep eight hours”: nice ideas, not happening this month. Then a small box
arrives from her clinic with a simple FIT kit, a prepaid envelope, and a text message that says (in Spanish) what to do and why it matters.
The instructions are clear. The process takes minutes. The real miracle? A follow-up call arrives two days laternot because she did something
wrong, but because she hasn’t mailed it back yet. The navigator isn’t scolding; they’re solving: “Do you need a new kit? Did the instructions
make sense? Do you want a reminder on Friday?” Maria sends it in. When the result comes back abnormal, the navigator already has a plan:
a colonoscopy appointment, a ride option, and a time that doesn’t require losing a full day of wages. Innovation didn’t replace care. It made
care easier to complete.

2) The mobile mammography visit that doesn’t require a miracle calendar

Denise lives in a rural area where the nearest imaging center is over an hour away. Between work, family, and a car that behaves like it’s
paid by the breakdown, annual screening feels like a luxury product. Then the mobile mammography unit shows up at a community event she was
already planning to attend. The appointment is fast. The staff speaks plainly, answers questions without rushing, and hands her a follow-up
number that actually connects to a person. A week later, when she gets results, there’s a clear next step and a navigator who can coordinate
additional imaging locally. The “innovation” wasn’t just a bus with a machine. It was the whole design: bringing screening to where people are,
pairing it with outreach, and making follow-up realistic. In Denise’s world, convenience is not a perk. It’s access.

3) Remote symptom check-ins that prevent the ER spiral

Jason is on chemotherapy and hates calling the clinic because he doesn’t want to “bother anyone.” He also doesn’t have the easiest time taking
off work for surprise appointments. His clinic enrolls him in a symptom monitoring program that texts him a short check-in twice a week.
One day he reports worsening shortness of breath and a fever. Within minutes, a nurse calls. They adjust his plan and get him evaluated before
the situation becomes a midnight emergency room sprint. Later, Jason says the best part wasn’t the technologyit was the feeling that someone
was watching out for him between visits. For patients with fewer resources, avoiding an ER visit isn’t just comfort. It’s fewer bills, fewer missed
work shifts, and fewer dominoes falling at once. When the tool works on a basic phone and the care team responds reliably, innovation becomes
a safety net, not a screen.

Across all three experiences, the pattern is the same: equity-first innovation reduces the number of “extra steps” a patient must survive.
It doesn’t assume perfect transportation, perfect internet, or perfect time. It quietly does what the health system too often forgets to do:
it adapts to peopleso people don’t have to adapt to it.